ATE533770T1 - Pyrazolopyrimidine als proteinkinaseinhibitoren - Google Patents

Pyrazolopyrimidine als proteinkinaseinhibitoren

Info

Publication number
ATE533770T1
ATE533770T1 AT06816408T AT06816408T ATE533770T1 AT E533770 T1 ATE533770 T1 AT E533770T1 AT 06816408 T AT06816408 T AT 06816408T AT 06816408 T AT06816408 T AT 06816408T AT E533770 T1 ATE533770 T1 AT E533770T1
Authority
AT
Austria
Prior art keywords
pyrazolopyrimidines
protein kinase
kinase inhibitors
inhibitors
protein
Prior art date
Application number
AT06816408T
Other languages
English (en)
Inventor
Kamil Paruch
Timothy Guzi
Michael Dwyer
Carmen Alvarez
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ATE533770T1 publication Critical patent/ATE533770T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT06816408T 2005-10-06 2006-10-04 Pyrazolopyrimidine als proteinkinaseinhibitoren ATE533770T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72419705P 2005-10-06 2005-10-06
PCT/US2006/039136 WO2007041712A1 (en) 2005-10-06 2006-10-04 Pyrazolopyrimidines as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE533770T1 true ATE533770T1 (de) 2011-12-15

Family

ID=37560916

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06816408T ATE533770T1 (de) 2005-10-06 2006-10-04 Pyrazolopyrimidine als proteinkinaseinhibitoren

Country Status (18)

Country Link
US (1) US7776865B2 (de)
EP (1) EP1931676B1 (de)
JP (2) JP5052518B2 (de)
KR (1) KR20080063806A (de)
CN (1) CN101321760A (de)
AR (1) AR056206A1 (de)
AT (1) ATE533770T1 (de)
AU (1) AU2006299338A1 (de)
BR (1) BRPI0617150A2 (de)
CA (1) CA2624882C (de)
EC (1) ECSP088350A (de)
IL (1) IL190598A0 (de)
NO (1) NO20082092L (de)
PE (1) PE20070543A1 (de)
RU (1) RU2008117298A (de)
TW (1) TW200745123A (de)
WO (1) WO2007041712A1 (de)
ZA (1) ZA200802995B (de)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070543A1 (es) * 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas
US20070082900A1 (en) * 2005-10-06 2007-04-12 Schering Corporation Methods for inhibiting protein kinases
KR20080106226A (ko) * 2006-03-08 2008-12-04 노파르티스 아게 신경계 장애의 치료에 있어서 피라졸로[1,5ａ]피리미딘-7-일 아민 유도체의 용도
CN101495481A (zh) * 2006-05-22 2009-07-29 先灵公司 作为CDK抑制剂的吡唑并[1,5-α]嘧啶
US8987233B2 (en) 2006-11-03 2015-03-24 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CN101600718B (zh) 2006-11-06 2013-07-03 特雷罗药物股份有限公司 咪唑并[1,2-b]哒嗪和吡唑并[1,5-a]嘧啶衍生物及其作为蛋白激酶抑制剂的用途
EP2409700A1 (de) 2007-05-08 2012-01-25 Schering Corporation Verfahren zur Behandlung mit intravenösen Formulierungen mit Temozolomid
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
WO2008141145A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
WO2008141140A1 (en) * 2007-05-09 2008-11-20 Abbott Laboratories Condensed heterocyclic compounds as inhibitors of protein kinases
EP2170886A1 (de) 2007-07-02 2010-04-07 Cancer Research Technology Limited 9H-PYRIMIDO[4,5-B]INDOLE, 9H-PYRIDO[4ý,3ý:4,5]PYRROLO[2,3-D]PYRIDINE UND 9H-1,3,6,9-TETRAAZAFLUORENE ALS INHIBITOREN DER FUNKTION VON CHK1-KINASE
AR069198A1 (es) * 2007-11-07 2010-01-06 Schering Corp Derivados de ribosil pirimidinas moduladores de quinasas de control chk1,y composiciones farmaceuticas que los comprenden utiles en el tratamiento del cancer.
US8426441B2 (en) * 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
CN101952283B (zh) * 2007-12-14 2013-04-17 霍夫曼-拉罗奇有限公司 咪唑并[1，2-a]吡啶和咪唑并[1，2-b]哒嗪衍生物
US8507501B2 (en) 2008-03-13 2013-08-13 The Brigham And Women's Hospital, Inc. Inhibitors of the BMP signaling pathway
JP2011519973A (ja) * 2008-05-12 2011-07-14 アムネスティックス・インコーポレーテッド 学習及び記憶を改善するための化合物関連出願に関する情報
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
PA8851101A1 (es) * 2008-12-16 2010-07-27 Lilly Co Eli Compuesto amino pirazol
KR20110114663A (ko) * 2009-02-13 2011-10-19 바이엘 파마 악티엔게젤샤프트 융합된 피리미딘
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
UA110324C2 (en) * 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
WO2011028638A1 (en) 2009-09-04 2011-03-10 Schering Corporation Modulators of cell cycle checkpoints and their use in combination with checkpoint kinase inhibitors
CN102711476B (zh) * 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
CA2805015A1 (en) * 2010-07-13 2012-01-19 Stuart Ince Bicyclic pyrimidines
CN103384670B (zh) * 2010-07-28 2016-05-25 拜耳知识产权有限责任公司 取代的咪唑并[1,2-b]哒嗪
JP2014517079A (ja) 2011-06-22 2014-07-17 バーテックス ファーマシューティカルズ インコーポレイテッド Ａｔｒキナーゼ阻害剤として有用な化合物
ES2671748T3 (es) 2011-07-21 2018-06-08 Tolero Pharmaceuticals, Inc. Inhibidores heterocíclicos de proteína quinasas
JP6073910B2 (ja) 2011-11-09 2017-02-01 キャンサー・リサーチ・テクノロジー・リミテッド ５−（ピリジン−２−イル−アミノ）−ピラジン−２−カルボニトリル化合物及びその治療使用
EP2802588B1 (de) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituierte pyrazolopyrimidine als akt kinase-inhibitore
DK2855448T3 (en) 2012-05-15 2017-05-01 Cancer Res Tech Ltd 5 - [[4 - [[MORPHOLIN-2-YL] METHYLAMINO] -5- (TRIFLUORMETHYL) -2-PYRIDYL] AMINO] PYRAZINE-2-CARBONITRIL AND THERAPEUTIC APPLICATIONS THEREOF
TR201807740T4 (tr) 2012-12-07 2018-06-21 Vertex Pharma ATR kinaz inhibitörü olarak 2-amino-6-fluoro-n-(5-fluoro-4-(4-(4-(oksetan-3-il)piperazin-1-karbonil)piperidin-1-il)piridin-3-il)pirazolo[1,5alfa]pirimidin-3-karboksamid.
ES2649156T3 (es) 2013-01-14 2018-01-10 Incyte Holdings Corporation Compuestos bicíclicos de carboxamida aromática útiles como inhibidores de quinasas Pim
CA2897333C (en) 2013-01-15 2021-07-06 Incyte Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
US9682983B2 (en) 2013-03-14 2017-06-20 The Brigham And Women's Hospital, Inc. BMP inhibitors and methods of use thereof
WO2014143241A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
EP2970286A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Kondensierte pyrazolopyrimidinderivate als inhibitoren der atr-kinase
EP2970288A1 (de) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Als atr-kinaseinhibitoren nützliche verbindungen
WO2015008844A1 (ja) 2013-07-18 2015-01-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
TR201907147T4 (tr) * 2013-07-18 2019-06-21 Taiho Pharmaceutical Co Ltd Fgfr inhibitörünün aralıklı uygulanmasına yönelik anti-tümör ilaç.
CR20160135A (es) 2013-08-23 2016-08-05 Incyte Corp Compuestos de carboxamida de furo y tienopiridina útiles como inhibidores de cinasas pim
WO2015085132A1 (en) 2013-12-06 2015-06-11 Vertex Pharmaceuticals Incorporated 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, its preparation, different solid forms and radiolabelled derivatives thereof
SI3152212T1 (sl) 2014-06-05 2020-06-30 Vertex Pharmaceuticals Inc. Radioaktivno označeni derivati 2-amino-6-fluoro-N-(5-fluoro-piridin-3-IL)-pirazolo (1,5-A)pirimidin-3- karboksamidne spojine, koristni kot inhibitor kinaze ATR, priprava navedene spojine in njene različne trdne oblike
LT3157566T (lt) 2014-06-17 2019-08-12 Vertex Pharmaceuticals Incorporated Vėžio gydymo būdas, panaudojant chk1 ir atr inhibitorių derinį
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US10513521B2 (en) 2014-07-15 2019-12-24 The Brigham And Women's Hospital, Inc. Compositions and methods for inhibiting BMP
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
PL3279202T3 (pl) 2015-03-31 2020-12-28 Taiho Pharmaceutical Co., Ltd. Kryształ 3,5-dipodstawionego związku benzenoalkinylowego
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
AU2016331955B2 (en) 2015-09-30 2022-07-21 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
TW201718546A (zh) 2015-10-02 2017-06-01 英塞特公司 適用作pim激酶抑制劑之雜環化合物
KR102793563B1 (ko) 2016-03-04 2025-04-11 다이호야쿠힌고교 가부시키가이샤 악성 종양 치료용 제제 및 조성물
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
CR20190520A (es) * 2017-05-22 2020-01-21 Hoffmann La Roche Composiciones y compuestos terapéuticos y métodos para utilizarlos
WO2019023468A1 (en) 2017-07-28 2019-01-31 Nimbus Lakshmi, Inc. TYK2 INHIBITORS AND USES THEREOF
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
MY203305A (en) 2018-03-19 2024-06-23 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
WO2019200254A1 (en) 2018-04-13 2019-10-17 Tolero Pharmaceuticals, Inc. Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer
CN108586341B (zh) * 2018-05-25 2020-05-08 天津商业大学 酰胺类化合物和其药用盐及其制备方法和药物用途
WO2020081508A1 (en) * 2018-10-15 2020-04-23 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
CN109293630A (zh) * 2018-11-15 2019-02-01 山东大学 含取代吡唑类化合物及其制备方法与应用
CA3127502A1 (en) 2019-02-12 2020-08-20 Sumitomo Dainippon Pharma Oncology, Inc. Formulations comprising heterocyclic protein kinase inhibitors
CN112457306A (zh) * 2019-09-06 2021-03-09 上海瑛派药业有限公司 3,5-二取代吡唑化合物作为激酶抑制剂及其应用
CN114957261B (zh) * 2022-05-17 2023-06-23 重庆文理学院 一种具有抗头颈癌作用的化合物及其制备方法和应用
CN120302975A (zh) 2022-10-31 2025-07-11 住友制药美国公司 治疗骨髓增生性肿瘤的pim1抑制剂
WO2025162425A1 (zh) * 2024-02-01 2025-08-07 广州费米子科技有限责任公司 吡唑并嘧啶化合物作为tyk2抑制剂

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3130633A1 (de) * 1981-08-01 1983-02-17 Basf Ag, 6700 Ludwigshafen 7-amino-azolo(1,5-a)pyrimidine und diese enthaltende fungizide
DE69130683T2 (de) 1991-04-22 1999-05-06 Otsuka Pharmaceutical Factory, Inc., Naruto, Tokushima PYRAZOLO[1,5-a]PYRIMIDINDERIVATE UND SIE ENTHALTENDE ANTIINFLAMMATORISCHE MITTEL
EP0628559B1 (de) 1993-06-10 2002-04-03 Beiersdorf-Lilly GmbH Pyrimidinverbindungen und ihre Verwendung als Pharmazeutika
US5571813A (en) 1993-06-10 1996-11-05 Beiersdorf-Lilly Gmbh Fused pyrimidine compounds and their use as pharmaceuticals
DE69523864T2 (de) 1994-06-21 2002-06-13 Otsuka Pharmaceutical Factory, Inc. PYRAZOLO[1,5-a] PYRIMIDIN-DERIVATE
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
EP0984692A4 (de) 1997-05-30 2001-02-21 Merck & Co Inc Angiogenese-inhibitoren
CA2314355A1 (en) 1997-12-13 1999-06-24 Bristol-Myers Squibb Company Use of pyrazolo ¢3,4-b! pyridine as cyclin dependent kinase inhibitors
US6413974B1 (en) 1998-02-26 2002-07-02 Aventis Pharmaceuticals Inc. 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
EP1140938B1 (de) 1999-01-11 2003-08-27 Princeton University Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
FR2805160B1 (fr) * 2000-02-23 2002-04-05 Oreal Compositions pour la teinture d'oxydation des fibres keratiniques comprenant un n(2-hydroxybenzene)-carbramate ou un n-(2-hydroxybenzene)-uree et une pyrazolopyrimidine, et procedes de teinture
CZ2003237A3 (cs) 2000-07-26 2003-06-18 Bristol-Myers Squibb Company N-(5-{[(5-Alkyl-2-oxazolyl)methyl]thio}-2-thiazolyl) karboxamidy jako inhibitory cyklin-dependentních kináz
EP1317453B1 (de) 2000-09-15 2006-08-09 Vertex Pharmaceuticals Incorporated Isoxazole und ihre verwendung als erk-inhibitoren
JP2002212076A (ja) * 2000-11-17 2002-07-31 Ishihara Sangyo Kaisha Ltd 縮合複素環化合物またはその塩を含有する糖尿病の予防または治療薬
US7067520B2 (en) * 2000-11-17 2006-06-27 Ishihara Sangyo Kaisha, Ltd. Preventive or therapeutic medicines for diabetes containing fused-heterocyclic compounds or their salts
US20040048849A1 (en) 2000-12-20 2004-03-11 Gregoire Prevost Cyclin-dependent kinase (cdk) and glycolene synthase kinase-3 (gsk-3) inhibitors
MXPA04010441A (es) 2002-04-23 2005-02-14 Shionogi & Co Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo.
DE10223917A1 (de) 2002-05-29 2003-12-11 Bayer Cropscience Ag Pyrazolopyrimidine
CA2487211C (en) 2002-06-04 2010-09-14 Neogenesis Pharmaceuticals, Inc. Pyrazolo(1,5a) pyrimidine compounds as antiviral agents
DK1537116T3 (da) * 2002-09-04 2010-09-27 Schering Corp Pyrazolopyrimidiner egnede til behandling af cancersygdomme
JP2006522750A (ja) 2003-04-11 2006-10-05 ノボ　ノルディスク　アクティーゼルスカブ 代謝性症候群ならびに関連の疾患および障害を治療するために、１１β−ヒドロキシステロイドデヒドロゲナーゼ１型阻害剤および抗高血圧剤を使用する併用療法
AR049769A1 (es) 2004-01-22 2006-09-06 Novartis Ag Derivados de pirazolo(1,5-a)pirimidin 7-il-amina para utilizarse en el tratamiento de enfermedades dependientes de la quinasa de proteina
WO2006078676A2 (en) * 2005-01-19 2006-07-27 Merck & Co., Inc. Bicyclic pyrimidines as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
GB0515026D0 (en) * 2005-07-21 2005-08-31 Novartis Ag Organic compounds
PE20070543A1 (es) * 2005-10-06 2007-06-14 Schering Corp Pirazolopirimidinas como inhibidores de protein quinasas

Also Published As

Publication number Publication date
JP5052518B2 (ja) 2012-10-17
WO2007041712A1 (en) 2007-04-12
JP2009511491A (ja) 2009-03-19
IL190598A0 (en) 2008-11-03
CN101321760A (zh) 2008-12-10
NO20082092L (no) 2008-07-04
CA2624882A1 (en) 2007-04-12
AR056206A1 (es) 2007-09-26
PE20070543A1 (es) 2007-06-14
US20070083044A1 (en) 2007-04-12
ECSP088350A (es) 2008-05-30
JP2012082233A (ja) 2012-04-26
TW200745123A (en) 2007-12-16
AU2006299338A1 (en) 2007-04-12
CA2624882C (en) 2014-05-20
EP1931676A1 (de) 2008-06-18
ZA200802995B (en) 2009-02-25
EP1931676B1 (de) 2011-11-16
BRPI0617150A2 (pt) 2011-07-12
KR20080063806A (ko) 2008-07-07
RU2008117298A (ru) 2009-11-20
US7776865B2 (en) 2010-08-17

Similar Documents

Publication Publication Date Title
ATE533770T1 (de) Pyrazolopyrimidine als proteinkinaseinhibitoren
ATE501142T1 (de) Als proteinkinaseinhibitoren geeignete phenylacetamide
IL191294A0 (en) Imidazopyrazines as protein kinase inhibitors
DK1951724T3 (da) Sammensmeltede bicykliske mTOR-inhibitorer
DE60314427D1 (de) Pyrazolopyrimidine als hemmstoffe cyclin-abhängiger kinasen
ATE479434T1 (de) Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine
DE60317077D1 (de) Pyrazolopyrimidine als hemmstoffe cyclin-abhängiger kinasen
DK1973910T3 (da) Pyrrolo[3,2-c]pyridin-4-on-2-indolinon-proteinkinaseinhibitorer
ATE443706T1 (de) Pyrrolotriazinverbindungen als kinaseinhibitoren
DK1720882T3 (da) Pyrazolopyrimidin-derivater som cyclin-afhængige kinaseinhibitorer
ATE518860T1 (de) Pyrroloä2,3-büpyridinderivate als proteinkinaseinhibitoren
ATE523499T1 (de) Cyclopenta [d]-pyrimidine als akt-proteinkinasehemmer
DE602004025258D1 (de) Aminotriazol-verbindungen als proteinkinase-hemmer
ATE524467T1 (de) Neuartige aza-heterozyklen als kinase-inhibitoren
ATE520671T1 (de) Pyrimidin-harnstoff-derivate als kinase-hemmer
TWI372625B (en) Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors
DE602005020465D1 (de) Enantiomerenreine aminoheteroaryl-verbindungen als proteinkinasehemmer
EP1951684A4 (de) Biarylmetapyrimidinkinaseinhibitoren
ATE530545T1 (de) Als kinaseinhibitoren geeignete pyrazolylaminopyridinderivate
ATE492544T1 (de) Pyrazol-substituierte aminoheteroarylverbindungen als proteinkinasehemmer
DE602005022115D1 (de) Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
ATE531705T1 (de) Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
ATE512972T1 (de) Pyrrolopyrazole als wirksame kinaseinhibitoren
ZA200709269B (en) Protein kinase inhibitors
EP1893607A4 (de) Checkpoint-kinasehemmer